Reading Time: 2 minutesIntroduction Obesity remains a significant public health concern in the United States, particularly among American males. The prevalence of obesity-related comorbidities, such as type 2 diabetes, cardiovascular diseases, and certain cancers, underscores the urgency for effective treatment strategies. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a promising therapeutic option. This article delves into a comparative analysis of semaglutide versus traditional therapies for obesity in American males, focusing on efficacy and side effects. Efficacy of Semaglutide Semaglutide has demonstrated remarkable efficacy in weight management among American males. Clinical trials, such as the STEP (Semaglutide Treatment Effect in People … Continue reading →